Soleno Therapeutics Inc [SLNO] stock prices are down -3.25% to $54.74 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The SLNO shares have gain 2.09% over the last week, with a monthly amount drifted -20.60%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Soleno Therapeutics Inc [NASDAQ: SLNO] stock has seen the most recent analyst activity on August 20, 2025, when Wells Fargo initiated its Overweight rating and assigned the stock a price target of $123. Previously, TD Cowen started tracking the stock with Buy rating on June 23, 2025, and set its price target to $110. Stifel reiterated its Buy rating but stick to its price target of $74 on December 02, 2024. Robert W. Baird reiterated its recommendation of a Outperform but $72 remained the price target by the analyst firm on December 02, 2024. H.C. Wainwright started tracking with a Buy rating for this stock on September 03, 2024, and assigned it a price target of $70. In a note dated May 10, 2024, Robert W. Baird initiated an Outperform rating and provided a target price of $72 on this stock.
The stock price of Soleno Therapeutics Inc [SLNO] has been fluctuating between $41.50 and $90.32 over the past year. Currently, Wall Street analysts expect the stock to reach $102.33 within the next 12 months. Soleno Therapeutics Inc [NASDAQ: SLNO] shares were valued at $54.74 at the most recent close of the market. An investor can expect a potential return of 86.94% based on the average SLNO price forecast.
Analyzing the SLNO fundamentals
Gross Profit Margin for this corporation currently stands at 0.98% with Operating Profit Margin at -5.87%, Pretax Profit Margin comes in at -5.54%, and Net Profit Margin reading is -5.54%. To continue investigating profitability, this company’s Return on Assets is posted at -0.54, Equity is -0.74 and Total Capital is -0.62. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.22.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Soleno Therapeutics Inc [NASDAQ:SLNO]’s Current Ratio is 15.13. In addition, the Quick Ratio stands at 15.01 and the Cash Ratio stands at 3.65. Considering the valuation of this stock, the price to sales ratio is 89.07, the price to book ratio is 11.50.
Transactions by insiders
Recent insider trading involved Abingworth Bioventures VII LP, Shareholder, that happened on Aug 11 ’25 when 1.35 million shares were purchased. Hirano Patricia C completed a deal on Jul 01 ’25 to sell 3830.0 shares. Meanwhile, Officer PATRICIA HIRANO bought 3830.0 shares on Jul 01 ’25.
